Economic recovery is putting this maker of premium footwear on a sound footing. Read More

This company is poised to gain from the huge projected need for medical-related isotopes. Read More

This drug firm could hold the key to ameliorating an intractable neurological disease. Read More

Prompted by Obamacare’s strictures, the dominant carriers in California are exiting the state’s individual health insurance market. Here’s what it all means for the health care industry in the Golden State. Read More

Its dramatic price decline, accompanied by extremely negative commentary, makes the "store of value" worth a new look. Read More

This fast-growing technology company is the best play on the growth in collaborative, video-based knowledge sharing. Read More

This Spanish biotech faces huge growth prospects for its leading edge treatments that could alleviate a host of intractable diseases. Read More

This innovative drug could finally help Americans prevail against their ever-expanding waistlines. Read More

Here’s what the latest euro zone crisis really means for investors. Read More

Although the drugmaker’s treatment for hepatitis C has shown great promise during clinical trials, investors still have time to take advantage of this stock before shares head higher in anticipation of the drug’s approval. Read More